Screening method
AssigneeIsis Innovation Limited
InventorsNicholas B. La Thangue, Susan Fotheringham
Life of this patent
Estimating the term…
Abstract
This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.
Claims17
-17. (canceled)
A method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor, the method comprising assessing the level of expression or activity of a gene or its expression products, or the sequence of a gene, in a sample from a patient and comparing said level of expression or activity or sequence to a reference, wherein a level of expression or activity or sequence that is different to said reference is indicative of an altered susceptibility to treatment with the HDAC inhibitor relative to the reference state, and wherein said gene is hHRAD23B (human rad 23B).
A kit comprising:
- (a) a first container containing a nucleic acid probe that hybridises under stringent conditions with an hHRAD23B nucleic acid molecule;
- (b) a second container containing primers useful for amplifying said nucleic acid molecule;
- and
- (c) instructions for using the probe and primers for facilitating diagnosis;
- or comprising:
- (a) a probe that hybridises under stringent conditions to hHRAD23B mRNA;
- and
- (b) a reagent which allows detection of formation of a complex between the mRNA and the probe;
- or comprising:
- (a) one or more antibodies that binds to hHRAD23B;
- and
- (b) a reagent useful for the detection of a binding reaction between the antibody and the protein.
Dependencies are inferred from the claim text.